NIH Reporter #5R50CA265331-04

Research Specialist Support for Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma

This opportunity from the National Cancer Institute (NCI) supports research into bone marrow adipocytes and FABP4/5 signaling in multiple myeloma. - Government Buyer: - National Cancer Institute (NCI), part of the US Department of Health and Human Services - Vendors and OEMs: - No specific OEMs or commercial vendors are named; the award is for a research specialist service - Products/Services Requested: - Research Specialist service to conduct studies on bone marrow adipocytes and FABP4/5 signaling - Utilization of 3D tissue-engineered cancer models with silk scaffolds - Mouse models to investigate myeloma-adipocyte interactions and tumor growth - Focus on drug resistance and tumor progression in multiple myeloma - Unique/Notable Requirements: - Emphasis on developing interventions to overcome drug resistance - Use of advanced tissue engineering and animal models - Project classified under CFDA code 93.395 - Estimated and awarded contract value: $99,576 - No specific product part numbers or quantities; the award is for a single research specialist service

Description

This solicitation seeks support for a Research Specialist to assist in studies aimed at understanding the role of bone marrow adipocytes and fatty acid-binding proteins FABP4 and FABP5 in multiple myeloma progression and drug resistance. The project involves using 3D tissue-engineered cancer models and mouse models to investigate tumor growth and drug resistance mechanisms. The goal is to develop interventions to overcome drug resistance and improve survival and quality of life for myeloma patients. The work is funded by the National Cancer Institute for fiscal year 2025.

View original listing